Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Roblox Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Roblox Corp trades at $55.3 (market cap $39.63B). The key difference: Alnylam Pharmaceuticals, Inc. and Roblox Corp are close in size by market cap. Which is the better fit depends on your goals.
| ALNY | RBLX | |
|---|---|---|
Market Cap | $39.89B | $39.63B |
Sector | Health | Media |
52-Week High | $491.22 | $141.56 |
52-Week Low | $278.09 | $41.30 |
Enterprise Value | $38.15B | $38.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Roblox (RBLX) trades at $55.35, down 1.9% on the day, amid a bullish technical signal and strong analyst support. The stock shows consistent revenue growth, with 2025 revenue reaching $4.89 billion, though it remains unprofitable with a net income margin of -20.69%. Recent earnings have beaten expectations, but the company faces headwinds from a securities class action lawsuit related to age-verification disclosures. Operating cash flow improved to $1.8 billion in 2025, signaling healthy core business operations despite ongoing losses.
The outlook for RBLX is mixed; robust user monetization and revenue growth present upside potential, supported by a consensus price target of $64.07. However, persistent losses, high valuation multiples like a P/B of 91.73, and legal risks weigh on investor confidence. The stock's trajectory hinges on achieving profitability and navigating regulatory scrutiny, making it a high-risk, growth-oriented play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
